"Disease Progression" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
| Descriptor ID |
D018450
|
| MeSH Number(s) |
C23.550.291.656
|
| Concept/Terms |
Disease Progression- Disease Progression
- Disease Progressions
- Progression, Disease
- Progressions, Disease
|
Below are MeSH descriptors whose meaning is more general than "Disease Progression".
Below are MeSH descriptors whose meaning is more specific than "Disease Progression".
This graph shows the total number of publications written about "Disease Progression" by people in this website by year, and whether "Disease Progression" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 10 | 10 |
| 1997 | 0 | 4 | 4 |
| 1998 | 0 | 10 | 10 |
| 1999 | 0 | 7 | 7 |
| 2000 | 0 | 16 | 16 |
| 2001 | 0 | 16 | 16 |
| 2002 | 0 | 19 | 19 |
| 2003 | 0 | 20 | 20 |
| 2004 | 0 | 35 | 35 |
| 2005 | 0 | 34 | 34 |
| 2006 | 0 | 46 | 46 |
| 2007 | 1 | 33 | 34 |
| 2008 | 0 | 40 | 40 |
| 2009 | 2 | 49 | 51 |
| 2010 | 3 | 47 | 50 |
| 2011 | 3 | 49 | 52 |
| 2012 | 2 | 58 | 60 |
| 2013 | 2 | 46 | 48 |
| 2014 | 4 | 54 | 58 |
| 2015 | 6 | 62 | 68 |
| 2016 | 3 | 55 | 58 |
| 2017 | 7 | 61 | 68 |
| 2018 | 10 | 69 | 79 |
| 2019 | 4 | 66 | 70 |
| 2020 | 4 | 52 | 56 |
| 2021 | 5 | 38 | 43 |
| 2022 | 1 | 24 | 25 |
| 2023 | 0 | 40 | 40 |
| 2024 | 12 | 19 | 31 |
| 2025 | 1 | 33 | 34 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Disease Progression" by people in Profiles.
-
ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease. Eur Respir J. 2026 Jan; 67(1).
-
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis. Blood Adv. 2025 Nov 11; 9(21):5654-5662.
-
Enhancing cardiac serine biosynthesis mitigates the progression of dilated cardiomyopathy in mice. Metabolism. 2026 Jan; 174:156395.
-
Treatable traits in interstitial lung disease: opportunities and challenges. Respir Med. 2025 Nov; 248:108353.
-
Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy. Mov Disord. 2025 Nov; 40(11):2517-2530.
-
Characteristics Associated with Lung Function Trajectories: An Analysis of the SPIROMICS Cohort. Ann Am Thorac Soc. 2025 Aug; 22(8):1165-1175.
-
Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics. Biochim Biophys Acta Rev Cancer. 2025 Oct; 1880(5):189396.
-
The Natural History Study and Biomarker Collection of the Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA). Cerebellum. 2025 Jul 18; 24(5):134.
-
Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy. Nat Genet. 2025 Aug; 57(8):1872-1880.
-
Caloric restriction promotes resolution of atherosclerosis in obese mice, while weight regain accelerates its progression. J Clin Invest. 2025 Sep 16; 135(18).